Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of contrast-induced acute kidney injury in acute coronary syndrome
IRCT20260910071000N1Phase 2Recruiting
- Sponsor
- Guilan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in acute coronary syndrome (ACS) (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Incidence of contrast-induced acute kidney injury. Started Oct 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20260910071000N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260910071000N1.